Context Therapeutics rises as clinical partner bags FDA approval

Context Therapeutics

31/01/2023 13:20

** Shares of drug developer Context Therapeutics Inc
 CNTX.O  rise 43% to $0.97 premarket
    ** The U.S. Food and Drug Administration approves
investigational drug Orserdu to treat certain types of breast
cancer
    ** Orserdu belongs to Stemline Therapeutics Inc, a
wholly-owned subsidiary of The Menarini Group
    ** CNTX's investigational drug ONA-XR is being evaluated in
an early stage study to enhance anti-cancer activity of Orserdu
    ** ONA-XR has not been approved for marketing by any
regulatory authority
    ** Stock has declined 65% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))